Nifurtimox treatment resulted in loss of ERK phosphorylation in PFSK-1 cells and in increased phosphorylation of MEK and ERK in glioblastoma cell lines at low doses of nifurtimox, followed by significant reduction of MEK and ERK phosphorylation at doses above the determined IC50 values in these cell lines (Fig. 3). Here, MAP2K7 is linked to glioblastoma.